Confronting autoimmune disease
In search of a new approach
Azadyne are a preclinical biotech company with a new approach to treating autoimmune disease. We have identified a new target within the body and a previously undrugged pathway. Using this approach, Azadyne are able to selectively control natural regulatory pathways to modify specific pathogenic immune populations. This mode of action offers therapeutic benefit in a range of indications and also has broader platform application.
Azadyne is a UK company founded in 2019 by Jason Rutt, Vincent Kelly, Stephen Connon & J Michael Southern. It is a spin-out from Trinity College Dublin, to exploit the pioneering work conducted in the Profs Kelly, Connon & Southern’s labs.
The company has received investment from VC and EIS investors.
Azadyne’s approach offers a new paradigm in the treatment of autoimmune disease
Azadyne’s novel and innovative approach to treating disease is characterized by some key features: